People who take the popular weight-loss drugs like Ozempic and Wegovy are 45% more likely to have suicidal thoughts than people taking other drugs, according to a study published Tuesday in the Journal of the American Medical Association (JAMA).
The issue of suicidal thoughts linked to weight-loss drugs has been a major hurdle to the drug industry’s ability to develop lucrative weight-loss drugs.
The overall number of suicidal thoughts reported was small, he said, but the proportion of cases where the thoughts stopped when the drug was stopped was high.
The researchers also found a higher risk for suicidal thoughts among people on antidepressants or benzodiazepines, likely prescribed for depression or anxiety, who were also taking semaglutide.
Novo Nordisk, the Danish pharmaceutical company that makes Ozempic, Wegovy and Saxenda only published its clinical trial showing weight loss effects of semaglutide in February of 2021 and the FDA approved Wegovy for weight loss in June 2021.
They compared reporting rates for semaglutide — the active ingredient in the blockbuster drugs — to other similar weight-loss drugs and all drugs in the database.
The popular weight-loss drugs, which contain the active ingredient semaglutide, were associated with “disproportionately increased reporting of suicidality,” according to a study published Tuesday in the Journal of the American Medical Association.
https://childrenshealthdefense.org/defender/semaglutide-ozempic-wegovy-depression-suicide-study/
No comments:
Post a Comment